A new treatment for rectal cancer is allowing some patients to avoid surgery. Doctors are seeing more young adults diagnosed ...

A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...

Intermountain Health is the first in the nation to use a new tool using a 3D computer model for rectal cancer surgery. The new technology, called Iris, guides surgeons during robotic rectal cancer ...

I was living a normal 29-year-old life. I thought my symptoms were no big deal, until they started happening more ...

Colorectal Surgeon Dr. Julio Garcia-Aguilar, MD, PhD (seated) with nurse Kieran Kelleher BSN-RN. Dr. Garcia-Aguilar and the colorectal service at MSK are experts at the watch and wait approach to ...

Robotic APR shows better short-term outcomes than laparoscopic APR, with lower positive resection margins and conversion rates to open surgery. Robotic APR is associated with longer operation times ...

Non-operative management achieved 95% distant relapse-free survival at 30 months in patients with stage II-III rectal cancer showing a clinical complete response to total neoadjuvant therapy, while ...

Although rectal cancer is a life-threatening disease, it is highly curable in its early stages. Depending on the location and state of the cancer, surgery may be required. To avoid life-altering ...

A new treatment for locally advanced rectal cancer shows favorable results in that surgery can sometimes be avoided completely. It also reduces the risk of recurrence. The method has been confirmed as ...

Please provide your email address to receive an email when new articles are posted on . Patients who started adjuvant chemotherapy more than 6 weeks after colorectal cancer surgery achieved poorer DFS ...

Real-world (RW) treatment patterns and clinical outcomes of patients treated with sequential regorafenib and trifluridine/tipiracil ± bevacizumab (BEV) for metastatic colorectal cancer (mCRC) in the ...

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...